Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

Fishbonee Dec. 24 at 3:43 PM

$RANI

1 · Reply

TheInside2028 Dec. 24 at 9:07 AM

$RANI Short Interest 10,601,934 shares - source: NASDAQ Short Interest Ratio 5.15 Days to Cover Short Interest % Float 14.14 % - source: NASDAQ (short interest), Capital IQ (float)

0 · Reply

llchen1204 Dec. 24 at 3:30 AM

$RANI

0 · Reply

Bakhm Dec. 23 at 7:17 PM

$RANI Why is there no official news that they will participate in the conference? Why is there no news that the exchange requirements have been met? You’ve fucking had enough of holding the price down — just buy however much is needed already and let it move

0 · Reply

Makingmillions192 Dec. 23 at 5:24 PM

$LEXX Guys the stock rocketing all depends on finding a big pharma partner. Look at $RANI it had great results but didn’t budged until their ~1B deal. We got the results - it’s everything we could have hoped for and efficacy was confirmed in earlier trials with SNAC. SNAC + DHT = best oral glp1 formulation in existence. Patience … 💰

0 · Reply

TheInside2028 Dec. 23 at 3:54 PM

$RANI we should be haulted and the RT-114 fast tracked. Hold for $10 in the super short term!!!! This proves the market!

0 · Reply

TheInside2028 Dec. 23 at 3:44 PM

$RANI sent inquiry to Mir Imran Executive Chairman at Rani Therapeutics Today Impact of Wegovy pill from Nova Nordisk: Good Morning-based on the news on Wegovy from Nova Norkisk on the pill format vs injection, is this a partnership in the works or a violation of RANI's patents. Does this fast track your pill RT-114 pipeline! Please respond as the investors are concerned that your company isn't getting the market share of this announcement or you're not updating any shareholder of the news.

1 · Reply

TheInside2028 Dec. 23 at 3:33 PM

$RANI [email protected] lets inundate IR

0 · Reply

TheInside2028 Dec. 23 at 3:25 PM

$RANI This news on NOVA seems to be either a partnership or an infringment on patents!!! Lily is next. The news should drop on effecacy on pil format! Watch for the announcement. Tolerability and efficacy is proven so should be fast tracked!

0 · Reply

pc247cz Dec. 23 at 2:50 PM

$RANI is one of my favourite stocks for 2026.

0 · Reply

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 6, 2025, 4:30 PM EST - 6 weeks ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Oct 30, 2025, 8:00 AM EDT - 7 weeks ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 23, 2025, 4:05 PM EDT - 2 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:01 PM EDT - 2 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 20, 2025, 2:20 PM EDT - 2 months ago

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

Oct 20, 2025, 9:42 AM EDT - 2 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Oct 17, 2025, 7:48 AM EDT - 2 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:31 AM EDT - 2 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:30 AM EDT - 2 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Jul 15, 2025, 9:00 AM EDT - 5 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 5 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

May 19, 2025, 8:00 AM EDT - 7 months ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 8 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Mar 31, 2025, 7:15 PM EDT - 9 months ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 9 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 9 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 9 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 14, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Mar 20, 2024, 7:05 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 8, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 24, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 10, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 5, 2023, 5:33 PM EDT - 2 years ago

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Fishbonee Dec. 24 at 3:43 PM

$RANI

1 · Reply

TheInside2028 Dec. 24 at 9:07 AM

$RANI Short Interest 10,601,934 shares - source: NASDAQ Short Interest Ratio 5.15 Days to Cover Short Interest % Float 14.14 % - source: NASDAQ (short interest), Capital IQ (float)

0 · Reply

llchen1204 Dec. 24 at 3:30 AM

$RANI

0 · Reply

Bakhm Dec. 23 at 7:17 PM

0 · Reply

Makingmillions192 Dec. 23 at 5:24 PM

0 · Reply

TheInside2028 Dec. 23 at 3:54 PM

$RANI we should be haulted and the RT-114 fast tracked. Hold for $10 in the super short term!!!! This proves the market!

0 · Reply

TheInside2028 Dec. 23 at 3:44 PM

1 · Reply

TheInside2028 Dec. 23 at 3:33 PM

$RANI [email protected] lets inundate IR

0 · Reply

TheInside2028 Dec. 23 at 3:25 PM

0 · Reply

pc247cz Dec. 23 at 2:50 PM

$RANI is one of my favourite stocks for 2026.

0 · Reply

Kp77_ Dec. 23 at 12:21 PM

$RANI keep loading

0 · Reply

Fishbonee Dec. 23 at 2:55 AM

$RANI - This is going to blow up again soon 📈

0 · Reply

wavw Dec. 23 at 12:40 AM

$RANI any impact of wegovy pill from nova nordisk.

1 · Reply

nowOrNever1 Dec. 22 at 11:20 PM

$RANI shorts have been trying daily. Macd ✔️ bull flag ✔️ shorts been covering before the bell daily ✔️ $NVO just released its oral ✔️ now its ur turn! Lets get it bulls!

0 · Reply

wavw Dec. 22 at 7:06 PM

$RANI something happening…bid is very high but the price not moving up

0 · Reply

KhokPiSDP Dec. 22 at 3:47 PM

$RANI last 3 days millions volume bought at market close bell ring.

0 · Reply

Bakhm Dec. 22 at 3:07 PM

$RANI I’m so fucking tired of you.

0 · Reply

SanJose2 Dec. 22 at 1:22 PM

$RANI

0 · Reply

wavw Dec. 22 at 12:38 PM

$RANI some update or new deal can trigger…waiting.

0 · Reply

Bullbear1010101 Dec. 22 at 12:51 AM

$RANI see 1.8 again or its done?

0 · Reply

Fishbonee Dec. 21 at 9:26 PM

$RANI - By the End of January 2026 📈

0 · Reply

TheInside2028 Dec. 20 at 1:52 PM

$RANI watch

0 · Reply

Market Cap	178.62M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,914.56%
Debt to Equity Ratio	-1.88

Volume	801,000
Avg Vol	23,322,482
Day's Range	N/A - N/A
Shares Out	121.51M
Stochastic %K	74%
Beta	0.40
Analysts	Strong Sell
Price Target	$9.25